Pay-per-procedure came for orthopaedics.

For twenty years, orthopaedic MedTech sold the way mainframe computing sold: put a large object in the building, then monetize everything that touches it. The robot is the visible version — seven-figure capital*, a service contract, and an implant catalog that only fits that platform. The quiet version is the same deal without the robot: instrument sets, loaner logistics, and a rep relationship, all priced into an implant invoice the facility pays whether the episode goes well or badly.

That model made sense for the seller. It never made sense for the buyer, because the buyer was never actually purchasing a device. The buyer was purchasing a procedure — one patient, one plan, one outcome — and paying for it as if buying infrastructure.

The device isn’t the product. The procedure is.

Cardiology worked this out first: the economics of a cath lab are organized around per-procedure consumption, and the commercial conversation follows the case, not the console. Orthopaedics arrived at the same place by a different road — the bundle. Once BPCI and CJR (and now the mandatory TEAM model) made the facility accountable for the whole episode, the unit of account stopped being “the implant” and became “the case.” Anything priced per-building instead of per-case is now a mismatch between how you pay and how you’re paid.

What pay-per-case changes for a center

• No capital wall. Personalized planning and patient-specific instrumentation arrive as a per-case service — software-driven planning through the standard regulatory route (the 510(k) pathway, not a capital program). There is no $1.5M* gate deciding which centers get access to personalization.
• No implant lock-in. When the plan is the product, the implant can be chosen on fit and price rather than on which platform the building already amortizes. Implant-agnostic planning restores the center’s negotiating position on its single largest supply cost.
• Cost that tracks accountability. Under two-sided risk, the facility keeps savings and eats overruns. A per-case fee sits inside the same episode ledger — you can see, case by case, whether it paid for itself. A depreciation schedule cannot answer that question.

The buy-side of the shift

Every MedTech commercial team is now rebuilding its model around procedures instead of platforms. MSKvalue is the buy-side of that same shift: we assemble the personalized episode — assessment, planning, monitored recovery, and the surgeon-side outcomes and billing layer at surgeonvalue.com — priced per case, so the center that owns the episode also owns its cost structure. The arithmetic of what a per-case fee returns inside a mandatory episode is worked through in the per-case economics post; the ASC-specific terms are on the ASC program page.

The mainframe era of orthopaedics is ending the way the mainframe era usually ends: not because the machines stopped working, but because the buyers stopped needing to own them.

Figures marked * are illustrative and program-dependent; not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.